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1. Introduction
The field of respiratory endoscopy has developed over the last decade. Endoscopy is now used
for early detection, diagnostic procedures, endoscopic ultrasound and endobronchial inter‐
ventions. Bronchoscopy is a standard procedure for endoscopists but recently new techniques
like autofluoresence bronchoscopy have been introduced. It is not known how these techni‐
ques should be incorporated in standard clinical care. Autofluorescence bronchoscopy can be
used for detection of premalignant lesions but it is known that the used histological classifi‐
cation does not correlate to biological behaviour. Premalignant lesions may regress or very
early abnormal lesions may progress into tumor. Therefore the work up of these lesions is not
known. To overcome this problem new techniques are introduced like optical coherence
tomography or incorporation of spectroscopy. The value of these techniques for daily practice
and research will be reviewed. We will discuss all the presently available techniques and there
indications.
Endobronchial ultrasound is a new technique used for staging in lung cancer or diagnostics
purposes. This technique offers impressive opportunities for endoscopists to perform minimal
invasive staining of the mediastinum and lung lesions adjacent to the bronchus. However the
exact role of the endobronchial ultrasound in staging of lung cancer has to be established. Also
although quite limited the technique can have complications which should be kept in mind
before performing this procedure. The indications and major drawbacks of this technique will
be discussed.
Endobronchial interventions have proven to be of mostly palliative value for individual
patients. As large randomised trials are lacking, lots of techniques are applied mostly depend‐
ing on local habits. However from published data some guideline can be given. We will review
the main endoscopic interventions and advise which technique to be used in which indication.
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2. EUS and EBUS in non-small cell lung cancer
The development of transesophageal endoscopic ultrasound-guided fine needle aspiration
(EUS-FNA) and transbronchial ultrasound real time guided needle aspiration (EBUS-TBNA)
have drastically altered lung cancer staging algorithms. Both are minimally invasive techni‐
ques that enable ultrasound controlled tissue sampling in addition or as an alternative to
surgical procedures. Tissue proof of presumed mediastinal spread is mandatory for accurate
diagnosis and staging as well as treatment planning. Imaging modalities such as computed
tomography (CT), positron emission tomography (PET) provide information regarding size
and metabolic activity, respectively, but are not accurate enough to be used in clinical practice.
Consequently, tissue diagnosis remains necessary. Mediastinoscopy is considered the stand‐
ard method for mediastinal lymph node staging, however drawbacks are its invasiveness,
requirement for general anesthesia, clinical admission and costs. The role of endosonography
is evolving rapidly, the aim of the following is to present the status of E(B)US based on a
literature survey.
2.1. EUS-FNA
Linear echo-endoscopes were originally developed for gastrointestinal diseases [1]. In 1995 it
became apparent that a considerable part of the middle and posterior mediastinum could be
reached and sampled [2] including lymph nodes paratracheal on the left (station 4L), in the
aortopulmonary window (station 5), para-aortal (station 6), subcarinally (station 7), lower
paraesophageal (station 8), pulmonary ligament (station 9), as well as the left adrenal gland.
Levels 2 and 4R are not always accessible. Specific sonographic features of lymph nodes (short
axis size >1cm, round shape, distinct margins, homogeneous echogenicity, absent central hilar
structure, coagulation necrosis) are more likely to contain metastasis [3] for which EUS has a
sensitivity, specificity, positive and negative predictive value of 78%, 71%, 75% and 79%
respectively [4]. EUS in combination with FNA however is more accurate, with a pooled
sensitivity of 83% and a pooled specificity of 97% [5]. Rapid on site evaluation by a cytopa‐
thologist (ROSE) has been shown to improve the diagnostic yield [6], if however on- site
cytology isn’t available, the optimal number of needle passes needed to obtain an optimal yield
is three [7]. EUS-FNA is usually performed in an ambulatory setting under local anaesthesia
and conscious sedation using midazolam. The procedure is considered safe as no serious
complications have been reported. FNA of a cystic lesion, however, should be avoided due to
the risk of mediastinitis [8, 9].
2.2. EBUS-TBNA
Sampling mediastinal lymph nodes through the tracheal carina using a rigid bronchoscope
was first described in 1949 [10]. In 1983 Wang reported the use of TBNA for lung cancer staging
[11]. The sensitivity varies between 39% and 78% depending on the prevalence of mediastinal
metastasis [12]. Despite being an available technique for over 50 years, TBNA has been
underused. The main reason for its limited use is the lack of real time needle visualization
causing numerous false negative results and complications [13]. Radial endobronchial
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ultrasound first described in 1992 has been shown to increase the yield of TBNA, however,
due to the nature of the probe it does not allow real time needle visualization [14]. Conversely,
the linear endobronchial ultrasound developed in 2002 could reach and sample para-tracheal
(stations 2 and 4), subcarinal (station 7), hilar and intrapulmonary nodes (stations 10 and 11)
[15]. Specific sonographic features of lymph nodes (short axis size >1cm, round shape, distinct
margins, homogeneous echogenicity, absent central hilar structure, coagulation necrosis) are
more likely to contain metastasis [16] for which EBUS-TBNA has a pooled sensitivity of 88%
and a pooled specificity of 100% [17]. Optimal results can be obtained in three aspirations per
lymph node. When at least one tissue core aspiration is obtained, two aspirations per lymph
node can be acceptable [18]. EBUS-TBNA is generally performed in a ambulatory setting under
local anaesthesia and conscious sedation using midazolam. To date, no major complications
have been reported.
2.3. Comparison of staging methods
Non-invasive methods such as CT and PET have limited sensitivity (57%) and specificity
(82%), with a positive predictive value of only 79% for detection of mediastinal lymph node
metastasis [4].  The combination of lymph node size and metabolic activity with PET/CT
improves accuracy, but does not eliminate the need for invasive testing [19]. For primary
mediastinal lymph node staging, the American College of Chest Physicians (ACCP) and
the  European  Society  of  Thoracic  Surgery  (ESTS)  consider  mediastinoscopy  the  gold
standard with a sensitivity of 78% and a negative predictive value of 88% [20, 21]. Although
considered a standard, there are limitations to its diagnostic reach. Stations 5, 6, posterior
part of 7, 8 and 9 are not accessible by cervical mediastinoscopy. Further limitations are
the requirement for general anesthesia, clinical admission, costs, as well as a reported 2%
risk morbidity [22].  Less invasive methods have emerged such as TBNA, EUS-FNA and
EBUS-TBNA. TBNA has a variable yield, is a ‘blind’ technique, and the results depend on
the size of the lymph node. In contrast,  real-time ultrasound-guided nodal aspiration by
EUS or EBUS has a higher sensitivity for mediastinal metastasis. In a comparison of EUS-
FNA and mediastinoscopy, both methods are just as accurate (91% versus 90%), but due
to their complementary reach, the combination of EUS-FNA and mediastinoscopy detect
significantly more patients with lymph node metastasis than either method alone [23]. EUS-
FNA prevented 50-70% of scheduled surgical procedures [24, 25]. Furthermore, in combin‐
ing EUS-FNA and EBUS-TBNA a near complete minimally invasive mediastinal  staging
can  be  achieved  with  a  higher  sensitivity  (93%)  and  negative  predictive  value  (97%)
compared  with  either  method alone  [26].  Strategies  with  an  EBUS-TBNA bronchoscope
placed first in the airway and then in the oesophagus can be just as useful with a sensitiv‐
ity of 96% and a negative predictive value of 95% [27]. Finally, a staging strategy combin‐
ing endosonography and surgical staging compared with surgical staging alone resulted
in greater sensitivity (94% versus 79%) for mediastinal metastasis and fewer unnecessary
thoracotomies  [28].  Cost–minimization  models  for  assessment  of  mediastinal  nodal
metastasis demonstrate that the pretest probability of nodal metastasis determines the most
cost  effective  strategy.  EUS alone or  combined with EBUS is  less  costly  compared with
surgical staging [29]. In a strategy using PET, EUS-FNA reduced staging costs by 40% by
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preventing surgical staging [30]. Given that the sensitivity of EUS-FNA and EBUS-TBNA
is similar to that of mediastinoscopy and that endosonography is less invasive, safe, and
more cost- effective, endosonography is now regarded as the initial staging procedure of
choice and incorporated in guidelines.
2.4. Conclusion
EUS-FNA and EBUS-TBNA enable complete ultrasound controlled mediastinal tissue
sampling in addition or as an alternative to surgical procedures and as such have drastically
altered lung cancer staging algorithms.
3. Therapeutic bronchoscopy in thoracic malignancies: Endobronchial
interventions
In the last decades multiple endobronchial intervention techniques have been developed for
the treatment of various pulmonary conditions and regaining airway patency. Especially in
patients with pulmonary malignant diseases and significant partial airway obstruction,
ensuring an open airway on a short notice is mandatory due to an increased risk of complete
obstruction and suffocation. A surgical approach is usually not feasible in these patients, as it
is mostly a palliative intervention. Also, significant comorbidities (i.e. COPD, heart failure)
often do not permit a surgical approach as such a procedure is accompanied with an increased
risk of severe complications. Therefore techniques are required that ensure a patent airway
with a minimal risk of complications.
Obstruction  of  the  airways  in  patients  with  thoracic  malignancies  is  caused  by  three
mechanisms:  1.  endoluminal  growth  of  neoplasms,  2.  compression  of  the  airway  by  a
malignant process, and 3. a combination of these two. Interventions in patients are aimed
at  debulking  of  tumorous  tissue  and  regaining  an  open  airway.  This  can  be  best  per‐
formed with rigid or flexible bronchoscopy and offers in most cases instant relief for the
patient.  Beneficial  features of flexible bronchoscopy compared to rigid bronchoscopy are
the lack of general anaesthesia and the easy access of the distal bronchi and the airways
of the upper lobes. However, rigid bronchoscopy enables control of ventilation during the
procedure, the removal of large fragments of tumorous tissue and stenting of the affect‐
ed airways [31]. Examples of the applied techniques during these interventions are laser
therapy, diathermia, argon plasma coagulation and the application of endobronchial stents.
Application of brachytherapy, cryotherapy and photodynamic therapy are in most cases
contraindicated for the treatment of lesions obstructing the airways, since they require time
to achieve their effects.
We will discuss the different advantages and disadvantages of each technique and also their
indications and contraindications. We will review their use in a palliative setting, but also




Electrocautery uses an electrical current to achieve its effects. The voltage difference between
probe and target tissue generates a flow of electrons. Due to resistance of the target tissue for
the electrons, heat is generated which is used for coagulation and tissue necrosis. The extend
of the effect of electrocautery on the target tissue depends of several factors [32]. First, the
smaller the contact area between probe and tissue, the more the current density is increased
and thereby the effect on the tissue. Second, the time the electrons are allowed to flow through
the tissue. Longer duration of application results in an increased effect. Third, the wattage or
voltage difference between probe and tissue. An increased wattage corresponds with an
increased flow of electrons and thus an increased effect. Reduction of the effect of electrocau‐
tery is due to the leakage of electrons via fluids and the metallic segments of the bronchoscope.
Compared with the YAG laser, electrocautery combines low costs [33] with easy to use features
in daily practice and a lower risk of airway perforation [34]. Contact of the probe with the
target tissue results in a similar effect as the YAG laser, although the extent of the effect is
different. As with argon plasma coagulation (see below), the electrons do not reach the deeper
tissue layers as compared with the photons of the YAG laser and therefore cause superficial
necrosis. Due to these properties, electrocautery is very suitable for regaining airway patency
in combination with mechanical debulking and stenting.
Since electrocautery causes superficial necrosis, it may be useful for the treatment of endo‐
bronchial carcinoma in situ and endoluminal superficial lung cancer [35]. Electrocautery
should also be considered for the treatment of granulomatous tissue and various other benign
lesions [36, 37].
Complications of electrocautery are endobronchial fires, especially when the fraction of
inspired oxygen is more than 0.4 and high wattage settings are used, and perforation of the
bronchial wall [34]. Contraindications for electrocautery are the same as for lasertherapy (see
below) [32].
3.1.2. Argon plasma coagulation
Argon plasma coagulation allows coagulation without making contact with tissue. It uses
ionised argon gas (plasma) to conduct electrons. These electrons do not reach the deeper layers
of tissue, in contrast with the scattering photons emitted by the Nd-YAG laser, and thereby
cause superficial coagulation/necrosis. A similar effect is achieved by the carbon dioxide laser.
Argon plasma coagulation can be used for coagulation, vaporisation and cutting. In patients
with airway obstruction by endobronchial tumour growth it should be combined with
mechanical debulking. Since its effect is superficial, it minimizes the risk of bleeding in areas
of the bronchial tree were major vessels rally just beneath the surface of the airway.
Due to its ability in achieving superficial necrosis, Argon plasma jet coagulation may be used
in a curative setting for the treatment of superficial lungcancer [38, 39].
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Complications of argon plasma coagulation are the same as with electrocautery. They include
endobronchial fires and bronchial wall perforation [40]. Contraindications are comparable
with the ones for laser surgery and electrocautery.
3.1.3. Laser resection
Laser resection of endobronchial lesions can be performed using rigid or flexible bronchosco‐
py. To date, the neodymium- yttrium aluminium garnet (Nd-YAG) laser is the most commonly
applied laser. Toty et al were one of the firsts to describe the use of the Nd-YAG laser for
patients with tracheal and bronchogenic cancer [41]. Since then several studies have evaluated
its role as an instrument to relieve obstruction and achieve haemostasis [42, 43].
During procedures the power setting should be limited to 40 W to prevent complications [31].
The tumorous tissue is first devascularised after which it can be removed. In relatively small
lesions a good strategy may be vaporisation of the whole lesion.
In contrast with the Nd-YAG laser the carbon dioxide laser has limited coagulation abilities.
Its most important advantage lies in its quality as a precise cutting instrument.
When laser surgery is performed during flexible bronchoscopy, general anaesthesia is in most
cases not required.
Advantages of the Nd-YAG laser are its ability to vaporise tissue and its excellence in coagu‐
lation. It disadvantages are the increased risk of perforation and the costs [33, 42]. Also
localisation of the tumor, especially in the upper bronchi, has a negative influence on the
success of the procedure [42].
Complications associated with endobronchial laser surgery are perforation, intraoperative
ventilation problems, post and intraoperative bleeding, postoperative infections, fistula
formation, endobronchial fire and even death [32, 42].
It is clear that laser therapy offers excellent opportunities for palliative care. Rapid relief of
dyspnoea and haemoptysis can be achieved in patients with endobronchial growth of a
malignancy. The only contraindication is external compression of the airways. Relative
contraindications are coagulopathy and hypoxemia [32]. Laser surgery can also be considered
in multiple non-malignant conditions [36]. Examples are stenosis due to trauma, sarcoidosis,
radiation therapy, granulation tissue and benign tumors.
3.1.4. Endobronchial stenting
To date, endobronchial and tracheal stent placement is being performed for already multiple
decades [44]. In these years various new stents have been developed ranging from bare metal
stents to covered metal stents and silicone stents. Due to the high rate of complications
associated with the use of bare metal stents, covered metal stents and silicone stents are now
being preferred by most interventional pulmonologists [45]. Unfortunately, comparative data
of the different stents is lacking. In almost all cases the choice of the applied stent is made by
the personal experience of the performing interventional pulmonologist.
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Some of the silicone stents, such as the Dumon stent [46], need to be placed by rigid broncho‐
scopy. This procedure requires general anestheisa. The self-expanding metal stents however,
do not require general anaesthesia and can be inserted during flexible bronchoscopy.
Stents are being used for ensuring an open airway in cases with extrinsic compression due to
neoplasms or after debulking of endobronchial malignancies. Furthermore, they can be
applied to cover malignant fistulas or iatrogenic fistulas after surgery and for fistulas between
the oesophagus and trachea.
Complications associated with endobronchial stenting are the increased production of mucoid
secretions, migration of the stent, the development of granulation tissue and the increased
chance of respiratory tract infections. Applying endobronchial stents is contraindicated if non-
viable lung is present beyond the obstruction [45].
4. Conclusion
We summarised the different endobronchial interventional tools for patients with pulmonary
malignancy. All the discussed methods have in common that they offer rapid relief of symp‐
toms. Differences exist in the costs and the ease of use of the various methods. Unfortunately,
no comparing data is available. Therefore the level of expertise of the interventional pulmo‐
nologist with a certain tool, the nature of the lesion and the associated risks should determine
which tool to use. When not available and intervention is mandatory, patients should be
referred to hospitals in which these procedures are being performed. It is clear that in the group
of patients with malignancies, the risk of severe complications exists. Patients should be
accordingly informed about these risks with in mind that in some cases time does not permit
less radical interventions.
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